Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
X-linked hypophosphatemia (XLH) is a rare, lifelong genetic bone disorder in which mutations in the PHEX gene drive excess FGF23, causing the kidneys to lose phosphate and leaving bones soft, weak, and poorly mineralized. Typical signs include rickets, bowed or curved legs, short stature, bone and joint pain, muscle weakness, dental abscesses, and hearing problems, though presentation differs by age and severity. Diagnosis usually involves blood and urine phosphate testing, X-rays, and genetic confirmation, while treatment may include targeted FGF23-blocking therapy, phosphate and active vitamin D supplements, and orthopedic or dental care. There are several important factors to consider, including how symptoms overlap with other bone and mineral conditions, so review the complete details below before drawing conclusions.
Because XLH symptoms are easy to mistake for growing pains, nutritional rickets, or ordinary joint problems, a fast and structured review of what you are experiencing can help you decide how urgently to seek care, and a free, instant, online symptom check can help you organize your symptoms and understand your next steps.
Last reviewed for medical accuracy: 08/18/2026
X-linked hypophosphatemia (XLH) is a rare genetic disorder that affects the way your body handles phosphate, a mineral critical for healthy bones and teeth. In XLH, low levels of phosphate in the blood lead to soft, weak bones—a condition often called rickets in children and osteomalacia in adults.
XLH is caused by a mutation in the PHEX gene, located on the X chromosome. This mutation disrupts normal phosphate regulation:
Because the gene is on the X chromosome:
XLH often becomes apparent in early childhood but may go undiagnosed until adulthood. Look out for:
Symptoms can vary in intensity. Some adults may notice joint stiffness, early osteoarthritis or fatigue rather than obvious bone deformities.
A healthcare provider will look at clinical signs and use tests to confirm XLH:
Early diagnosis helps start treatment sooner, reducing complications.
Managing XLH focuses on restoring phosphate balance and supporting bone health. Common therapies include:
Many people benefit from a multidisciplinary team: endocrinologists, orthopedic surgeons, dentists, and physical therapists.
In addition to medical treatments, these measures can help you manage XLH:
With proper care, many people lead active lives. However, be aware of:
Regular follow-up with your healthcare team helps catch and manage these issues early.
Adjusting to life with XLH involves:
Talking with others who have XLH can offer practical tips and emotional support.
Monitor for any new or worsening symptoms. If you experience:
…seek medical attention promptly. If you’re ever unsure whether your symptoms are serious, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
XLH was once thought untreatable, but research has brought promising advances:
Early detection and modern treatments mean many people with XLH can enjoy better growth, less pain and stronger bones than ever before.
Note: This information is intended for educational purposes and should not replace professional medical advice. Always speak to a doctor about any condition that could be life threatening or serious.
(References)
* Haffner D, Emma F, Eastwood DM, Biosse Duplan M, Bacchetta J, Schnabel D, Wicart P, Bockenhauer D, Santos F, Levtchenko E, Harvengt P, Kirchhoff M, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenicky P, Rejnmark L, Linglart A. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019 Jul;15(7):435-455. doi: 10.1038/s41581-019-0152-5. PMID: 31068690; PMCID: PMC7136170.
* Linglart A, Briot K. X-linked hypophosphatemia, a genetic and treatable cause of rickets! Arch Pediatr. 2021 Oct;28(7):587. doi: 10.1016/j.arcped.2021.08.008. Epub 2021 Sep 26. PMID: 34583870.
* Rush ET, Johnson B, Aradhya S, Beltran D, Bristow SL, Eisenbeis S, Guerra NE, Krolczyk S, Miller N, Morales A, Ramesan P, Sarafrazi S, Truty R, Dahir K. Molecular Diagnoses of X-Linked and Other Genetic Hypophosphatemias: Results From a Sponsored Genetic Testing Program. J Bone Miner Res. 2022 Feb;37(2):202-214. doi: 10.1002/jbmr.4454. Epub 2021 Nov 10. PMID: 34633109; PMCID: PMC9298723.
* Ackah SA, Imel EA. Approach to Hypophosphatemic Rickets. J Clin Endocrinol Metab. 2022 Dec 17;108(1):209-220. doi: 10.1210/clinem/dgac488. PMID: 35981346; PMCID: PMC9759174.
* Ito N, Hidaka N, Kato H. The pathophysiology of hypophosphatemia. Best Pract Res Clin Endocrinol Metab. 2024 Mar;38(2):101851. doi: 10.1016/j.beem.2023.101851. Epub 2023 Nov 30. PMID: 38087658.
* Haffner D, Emma F, Seefried L, Högler W, Javaid KM, Bockenhauer D, Bacchetta J, Eastwood D, Biosse Duplan M, Schnabel D, Wicart P, Ariceta G, Levtchenko E, Harvengt P, Kirchhoff M, Gardiner O, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenický P, Rejnmark L, Linglart A. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2025 May;21(5):330-354. doi: 10.1038/s41581-024-00926-x. Epub 2025 Jan 15. PMID: 39814982.
* Ali DS, Carpenter TO, Imel EA, Ward LM, Appelman-Dijkstra NM, Chaussain C, Jan de Beur SM, Florenzano P, Abu Alrob H, Aldabagh R, Alexander RT, Alsarraf F, Beck-Nielsen SS, Biosse-Duplan M, Crowley RK, Dandurand K, Filler G, Friedlander L, Fukumoto S, Gagnon C, Goodyer P, Grasemann C, Grimbly C, Hussein S, Javaid MK, Khan S, Khan A, Lehman A, Lems WF, Lewiecki EM, McDonnell C, Mirza RD, Morgante E, Morrison A, Portale AA, Rao C, Rhee Y, Rush ET, Siggelkow H, Tetradis S, Tosi L, Guyatt G, Brandi ML, Khan AA. X-Linked Hypophosphatemia Management in Children: An International Working Group Clinical Practice Guideline. J Clin Endocrinol Metab. 2025 Jun 17;110(7):2055-2070. doi: 10.1210/clinem/dgaf093. PMID: 39960858; PMCID: PMC12187519.
* Khan AA, Ali DS, Appelman-Dijkstra NM, Carpenter TO, Chaussain C, Imel EA, Jan de Beur SM, Florenzano P, Abu Alrob H, Aldabagh R, Alexander RT, Alsarraf F, Beck-Nielsen SS, Biosse-Duplan M, Cohen-Solal M, Crowley RK, Dandurand K, Filler G, Friedlander L, Fukumoto S, Gagnon C, Goodyer P, Grasemann C, Grimbly C, Hussein S, Javaid MK, Khan S, Khan A, Lehman A, Lems WF, Lewiecki EM, McDonnell C, Mirza RD, Morgante E, Morrison A, Portale AA, Rhee Y, Rush ET, Siggelkow H, Tetradis S, Tosi L, Ward LM, Guyatt G, Brandi ML. X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline. J Clin Endocrinol Metab. 2025 Jul 15;110(8):2353-2370. doi: 10.1210/clinem/dgaf170. PMID: 40243526; PMCID: PMC12261105.
* Böckmann I, Haffner D. The Diagnosis and Therapy of XLH. Calcif Tissue Int. 2025 Apr 28;116(1):66. doi: 10.1007/s00223-025-01374-w. Epub 2025 Apr 28. PMID: 40295317; PMCID: PMC12037658.
* Baroncelli GI, Barale M, Brandi ML, Camozzi V, Carrara S, Nicoletti MC, Castellano E, Cetani F, Comberiati P, Iorgi ND, Eller-Vainicher C, Emma F, Fintini D, Giannini S, Gianotti L, Grandone A, Grassi G, Mora S, Palermo A, Pigliaru F, Pitea M, Procopio M, Rochira V, Ruggeri RM, Ruggiero B, Stagi S, Vezzoli G, Corbetta S. Experts' consensus on the management and treatment of individuals with X-linked hypophosphatemia across lifespan. J Endocrinol Invest. 2025 Oct;48(10):2199-2228. doi: 10.1007/s40618-025-02611-7. Epub 2025 Jul 1. PMID: 40591205; PMCID: PMC12518444.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.